International Diabetes Federation. IDF diabetes atlas ninth edition 2019. https://diabetesatlas.org/en/resources/. Accessed 28 May 2020.
Google Scholar
Weng J, Ji L, Jia W, Lu J, Zhou Z, Zou D, et al. Standards of care for type 2 diabetes in China. Diab Metab Res Rev. 2016;32:442–58.
Article
Google Scholar
Ji L, Lu J, Weng J, Jia W, Tian H, Zhu D, Xing X, Guo L. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes. 2015;7:166–73.
Article
PubMed
CAS
Google Scholar
Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800–5.
Article
PubMed
Google Scholar
Kuo YF, Raji MA, Markides KS, Ray LA, Espino DV, Goodwin JS. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care. 2003;26:3054–60.
Article
PubMed
Google Scholar
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–30.
Article
PubMed
Google Scholar
Hao G. Cost-effectiveness of oral hypoglycemic drugs in the treatment of type 2 diabetes based on Bayesian mixed treatment comparison. Beijing: Beijing University of Chinese Medicine; 2014.
Google Scholar
McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin. 2006;22:121–9.
Article
PubMed
Google Scholar
McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diab Obes Metab. 2010;12:623–30.
Article
CAS
Google Scholar
The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diab Care. 2007;30:1638–46.
Article
Google Scholar
McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diab Obe Metab. 2010;12:431–6.
Article
CAS
Google Scholar
McEwan P, Bergenheim K, Yuan Y, Tetlow A, Gordon J. Assessing the relationship between computational speed and precision. Pharmacoeconomics. 2010;28:665–74.
Article
PubMed
Google Scholar
Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–59.
Article
PubMed
CAS
Google Scholar
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925–33.
Article
PubMed
CAS
Google Scholar
World Health Organization. The world health report 2002 - Chapter 5. http://www.who.int/whr/2002/en/Chapter5.pdf?ua=1. Accessed 1 Jan 2018.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes (fourth edition). Oxford: Oxford University Press; 2015.
Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415–30.
Article
PubMed
Google Scholar
Trippoli S. Incremental cost-effectiveness ratio and net monetary benefit: current use in pharmacoeconomics and future perspectives. Eur J Int Med. 2017;43:e36.
Article
Google Scholar
National Bureau of Statistics of China. Gross Domestic Product (GDP) per capita. http://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj=2019. Accessed 15 Apr 2020.
Chinese Group for Pharmacoeconomic Evaluations Guidelines. China guidelines for pharmacoeconomic evaluations (2020 Chinese-English version). 1st ed. Beijing: China Market Press; 2020.
Google Scholar
Cai X, Hu D, Pan C, Li G, Lu J, Ji Q, et al. Evaluation of effectiveness of treatment paradigm for newly diagnosed type 2 diabetes patients in Chin: a nationwide prospective cohort study. J Diab Investig. 2020;11:151–61.
Article
CAS
Google Scholar
Cai X, Hu D, Pan C, Li G, Lu J, Ji Q, et al. The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ a nationwide prospective cohort study. Sci Rep. 2019;9:7709.
Article
PubMed
PubMed Central
CAS
Google Scholar
Integrated Management Platform of Beijing Medicine Sunshine Purchase. http://210.73.89.76/ServiceSelect/GetServiceSelectList. Accessed 5 May 2018.
Zhang Y, Wu J, Chen Y, Shi L. EQ-5D-3L decrements by diabetes complications and comorbidities in China. Diabetes Ther. 2020;11:939–50.
Article
PubMed
PubMed Central
Google Scholar
Zheng YM, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Serv Adm. 2012;32:1195–8.
Google Scholar
Rajan N, Boye KS, Gibbs M, Lee YJ, Davey P, Ball M, Babineaux SM. Utilities for type 2 diabetes treatment-related attributes in a South Korean and Taiwanese population. Value Health Reg Issues. 2016;9:67–71.
Article
PubMed
Google Scholar
Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217–30.
Article
PubMed
Google Scholar
Guo H, Li J, Jiang Z. Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients. Chinese J Rehabil Med. 2007;22:395–8.
CAS
Google Scholar
Joint committee on revision of standards of medical care for adult dyslipidemia in China. Standards of medical care for adult dyslipidemia in China (2016 version). Chinese Circ J. 2016;31:937–53.
National Health Commission of the People’s Republic of China. Criteria of weight for adults. http://www.nhc.gov.cn/wjw/yingyang/201308/a233d450fdbc47c5ad4f08b7e394d1e8.shtml. Accessed 1 Sept 2020.
The Organisation for Economic Co-operation and Development (OECD). Exchange rates. https://data.oecd.org/conversion/exchange-rates.htm. Accessed 15 Apr 2020.
Bai N. The efficacy and side effects of metformin in the treatment of type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. China Health Standard Manage. 2016;7:78–80.
Google Scholar
Ruan Y, Tan QY, Ruan Y, Wang XJ, Yao J, Wang HL, Wang J. Clinical observation of metformin in the treatment of type 2 diabetes with non-alcoholic fatty liver disease. China Pharm. 2015;26:4659–61.
CAS
Google Scholar
Guo W, Gao MS, Ye ZH, Li Y, Tu JJ, Lei WM. Effects of metformin on the serum nesfatin-1 and liver steatosis in type 2 diabetic patients with nonalcoholic fatty liver disease. Chinese J Difficult Complicated Cases. 2014;13:374–7.
CAS
Google Scholar
Li L, Zhu K, Qu J, Xia A, Zhang W. Clinical effect of liraglutide and metformin hydrochloride on overweight diabetic patients with poor glycemic control. Clin Med China. 2014;30:67–9.
CAS
Google Scholar
Guo DL. Analysis of the efficacy of metformin in the treatment of type 2 diabetes. Diab New World. 2014;34:1–2.
Yang WC, Dang Y, Qiao L, Wang H, Li CQ, Dang XY. Effects of exercise therapy and metformin in newly diagnosed type 2 diabetes. J Henan Normal Univ. 2013;41:122–6.
CAS
Google Scholar
Liu YT, Hu B, Jian L, Li JW, Huang L. Influence of metformin on the level of serum vaspin in T2DM patients. Chinese J Diab. 2013;21:705–8.
CAS
Google Scholar
Xi Y. Efficacy of liraglutide in patients with newly diagnosed type 2 diabetes and obesity and its influence on their micro-inflammation. Chinese Gen Pract. 2013;16:3339–3340+3345.
CAS
Google Scholar
Chen Y. The level of visfatin in adipo-patients with type 2 diabetes mellitus and the influence of pioglitazone on it. Master. Guangdong: Guangdong Medical University; 2008.
Deng HO, Lin K, Li DF, Li YL. Effect of metformin on serum testosterone in male patients with type 2 diabetes. Guangdong Med J. 2007;28:601–2.
Google Scholar
Li HZ, Zhang C, Wang M, Liu XH. Effect of metformin and Avandia on lipid metabolism in patients with type 2 diabetes. J Clin Res. 2007;24:319–21.
Google Scholar
Mei Q. Therapeutic effect of metformin on type 2 diabetes mellitus complicated with nonalcoholic fatty liver. Pract Pharm Clin Remedies. 2006;9:346–7.
Google Scholar
Wang L, Ning J. Effects of metformin on C-reactive protein and complement factor C3 in obese patients with type 2 diabetes. Shanxi Med J. 2006;35:888–9.
CAS
Google Scholar
Wu GT, Han YQ, Wang JY, Li WJ, Gu Y, Shi Y. Effects of metformin on insulin resistance in type 2 diabetes mellitus patients. J Tongji Univ. 2001;22:31–32+35.
Google Scholar
Qu JC, Zhu KS, Wang T, Li L, Zhao L. Effect of rosiglitazone and metformin on lipid metabolism in patients with type 2 diabetes. China Med. 2011;6:286–7.
Google Scholar
Guo M, Mi J, Jiang Q, Xu J, Tang Y, Tian G, Wang B. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol. 2014;41:650–6.
PubMed
CAS
Google Scholar
Wang JP. Clinical observation of metformin combined with acarbose in the treatment of type 2 diabetes. Guide China Med. 2016;14:141–2.
Google Scholar
Han JK, Pang WY, Yang XZ, Xue L. The clinical observation of metformin combined with acarbose in patients with type 2 diabetes. China Health Standard Manag. 2016;7:116–8.
Google Scholar
Wang HY. Clinical efficacy of acarbose in the adjuvant treatment of type 2 diabetes. Chinese J Convalescent Med. 2016;25:71–2.
CAS
Google Scholar
Kong LL. Clinical efficacy of metformin combined with acarbose in the treatment of type 2 diabetes. Med Hygiene. 2016;2:163.
Zeng BF. Efficacy and prognosis of acarbose combined with metformin in patients with type 2 diabetes complicated with coronary heart disease. Harbin Med J. 2016;36:159–60.
Google Scholar
Liu J. Clinical observation of acarbose combined with metformin in the treatment of type 2 diabetes. Med Forum. 2015;19:5047–9.
Google Scholar
Wang XQ. Efficacy of acarbose combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes and hyperlipidemia. J Pract Gynecol Endocrinol. 2015;2:172–3.
Google Scholar
Li QD. Clinical analysis of acarbose combined with metformin in the treatment of type 2 diabetes. Diab New World. 2015;35:59–60.
Liu P. Clinical observation of glucobay combined with metformin in the treatment of type 2 diabetes. Guide China Med. 2015;13:71–2.
Google Scholar
Huang LY, Liao B, Yang M, Liu JH, Quan HM, Qin AP. Efficacy of acarbose combined with metformin in the treatment of newly diagnosed type 2 diabetes with hyperlipidemia. Med Aesthetics Beauty. 2015;24:211.
Su ZL. Clinical effect of metformin and acarbose in the treatment of obesity and diabetes. Med Inf. 2015;28:23.
Google Scholar
A YC. The effects of acarbose combined with metformin on blood glucose and blood fat of patients with type 2 diabetes. Diab New World. 2015;35:25–7.
Tan YL, Huang YN. Effect of acarbose combined with metformin on blood glucose control and islet function in elderly patients with refractory type 2 diabetes. Clin Med Eng. 2014;21:1422–6.
Zheng Q, Huangfu YH. Clinical observation of acarbose combined with metformin in the treatment of type 2 diabetes. China Pharm. 2014;25:2251–3.
CAS
Google Scholar
Zeng XY. Effect of acarbose combined with metformin in the treatment of elderly patients with type 2 diabetes. Jilin Med J. 2014;35:2159–60.
CAS
Google Scholar
Zhou XH, Zhong J, Ye D. The efficacy of acarbose combined with metformin in treatment of type 2 diabetes. China Modern Doctor. 2013;51:68–70.
Google Scholar
Liang JH, Chen LZ, Gong ZZ. Efficacy of metformin sustained-release tablets combined with acarbose in the treatment of obese type 2 diabetes. J Guangdong Med Coll. 2012;30:192–3.
Google Scholar
Zhang MH. Effects of metformin and acarbose on insulin resistance in patients with type 2 diabetes. Jilin Med J. 2011;32:3682–3.
CAS
Google Scholar
Zhu ZL, Qiu XC, Zhu HP, Ding ZJ. Application of acarbose combined with metformin in treatment of newly diagnosed type 2 diabetes patients. Heilongjiang Med J. 2011;24:223–5.
Google Scholar
Zheng YB, Zhou HY, Wu XB. Observation of voglibose combined with metformin in the treatment of newly diagnosed obese type 2 diabetes. Strait Pharmaceutical J. 2010;22:117–8.
Google Scholar
He K, Liu LH, Ji SM. Efficacy observation of miglitol combined with metformin in the treatment of type 2 diabetes mellitus. Chinese J Clin Ration Drug Use. 2016;9:1–2.
CAS
Google Scholar
Huang Y. Efficacy of miglitol combined with metformin in the treatment of type 2 diabetes. Chinese Baby. 2015;(4):206–7.
He K, Liu LH, Shi ZN, Yuan YH. Efficacy of miglitol combined with metformin in the treatment of type 2 diabetes. People’s Military Surg. 2014;57:1216–7.
Google Scholar
Shao HM. Comparison of the effect of glyburide and metformin in the treatment of type 2 diabetes. For all Health. 2015;9:118.
Google Scholar
Mao ZH, Tai SEGL. The effect of glimepiride combined with metformin on insulin resistance in patient with type 2 diabetes. Chinese Foreign Med Res. 2016;14:134–5.
Google Scholar
Xu YX. Efficacy of glimepiride combined with metformin in the treatment of type 2 diabetes. Modern Diagn Treat. 2016;27:4046–7.
CAS
Google Scholar
Ma CH. Influence of liraglutide on insulin resistance in patients with type 2 diabetes mellitus. Master. Xinjiang: Xinjiang Medical University; 2016.
Google Scholar
Yang GM, Wang WN. Clinical observation of metformin combined with glimepiride in the treatment of type 2 diabetes. China Med Pharm. 2016;6:145–7.
Google Scholar
Yang QF, Nie FR, Xu WL. The clinical efficacy and safety of metformin combined with liraglutide in the treatment of type 2 diabetes mellitus. Lingnan J Emerg Med. 2016;21:40–2.
Google Scholar
Xu YJ. Clinical observation of glimepiride combined with metformin in the treatment of 39 cases of type 2 diabetes. Chinese J Ethnomed Ethnopharm. 2015;24:85.
Google Scholar
Sun SJ. Clinical observation of glimepiride and metformin in the treatment of type 2 diabetes. Jilin Med J. 2014;35:948–9.
Google Scholar
Li X. Efficacy of glimepiride combined with metformin in the treatment of type 2 diabetes. Clin Med. 2012;32:57–8.
CAS
Google Scholar
Wang Y. Efficacy and safety of metformin combined with glimepiride in the treatment of new-onset type 2 diabetes. China Pract Med. 2012;7:186–7.
Google Scholar
Zhao HY. Efficacy of different drugs combined with metformin in the treatment of new-onset type 2 diabetes. Modern J Integr Tradit Chinese Western Med. 2012;21:2785–7.
CAS
Google Scholar
Ning J, Tang WL, Zhou ZG, Feng Q, Liu YH, Zhou WD. Effect of glimepiride and metformin on insulin resistance in type 2 diabetes. China J Modern Med. 2006;16:2224–7.
Wang J. Clinical efficacy of glimepiride combined with metformin in the treatment of type 2 diabetes. Med J Liaoning. 2015;29:177–8.
Google Scholar
Su YS. Efficacy of metformin combined with gliclazide in the treatment of type 2 diabetes. Shenzhen J Integr Tradit Chinese Western Med. 2016;26:126–7.
Google Scholar
Wei J. Clinical effect of gliclazide combined with metformin in the treatment of type 2 diabetes. J Clin Med Lit. 2015;2:322.
Google Scholar
Guo YP. Clinical effect of gliclazide combined with metformin in the treatment of type 2 diabetes. World Latest Med Information. 2015;15:105+108.
Google Scholar
Qin SL, Zhu B, Xu X, Tang YH, Zhu Z. Effect of gliclazide sustained-release tablets on the glucose and PAI-1 of patients with new-onset type 2 diabetes mellitus. J Clin Med Pract. 2014;18:11–3.
CAS
Google Scholar
Luo JY, Wu K. Clinical efficacy of gliclazide combined with metformin in the treatment of new-onset type 2 diabetes. Jilin Med J. 2014;35:8051–2.
CAS
Google Scholar
Wei J. Efficacy and safety of metformin combined with gliclazide sustained-release tablets in the treatment of type 2 diabetes. J Front Med. 2013;3:207.
Zhang JF. Clinical experience of gliclazide sustained-release tablets combined with metformin in the treatment of type 2 diabetes. Contemp Med. 2013;19:90–1.
Google Scholar
He F. Clinical efficacy of metformin combined with gliclazide sustained-release tablets in the treatment of type 2 diabetes. Gems of Health. 2013;(7):420.
Teng YP, Zhang Q, Ma YF. Gliclazide sustained-release tablets in the treatment of 86 cases of new-onset type 2 diabetes. China Med Pharm. 2012;2:34–5.
Google Scholar
Luo ZZ, Wang YL, He SX. Clinical efficacy of metformin combined with gliclazide sustained release capsule in the treatment of type 2 diabetes. China Med Pharm. 2012;2:100–1.
Google Scholar
Zhong XX. Efficacy of gliclazide combined with metformin in the treatment of type 2 diabetes mellitus. J Qiqihar Univ Med. 2012;33:2787–8.
Google Scholar
Xu QL, Huang CX. Clinical observation of gliclazide combined with metformin in the treatment of obese type 2 diabetes. China Pract Med. 2007;2:99–100.
Google Scholar
Xu H. Efficacy of metformin combined with gliclazide in the treatment of type 2 diabetes. Contemp Med Forum. 2015;13:281–2.
Google Scholar
Mei Z, Cheng Y. Clinical efficacy of glipizide (Disha Tablets) combined with metformin in the treatment of type 2 diabetes. China Health Care Nutr. 2014;24:2390.
Google Scholar
Zhao Y. Efficacy of glipizide combined with metformin in the treatment of new-onset type 2 diabetes. Chinese J Med. 2014;49:69–71.
CAS
Google Scholar
Sun R, Pan BB, Su XF, Ma JH. Observation of the effects of metformin and/or glipizide on 8-isoprostaglandin F2α and blood glucose levels in patients with type 2 diabetes. Chinese J Diab. 2013;21:60–2.
CAS
Google Scholar
Guo SB, Gao SX. Clinical efficacy of metformin plus glipizide on the patients with type 2 diabetes mellitus. Med Recapitulate. 2012;18:1606–7.
Google Scholar
Li P, Chen W, Li L, Liu C, Shan ZY, Su BL, Ge HQ. Glipizide/metformin therapy for patients with type 2 diabetes: a multi-center, randomized double-masked study. Chinese Pharm J. 2011;46:1362–5.
CAS
Google Scholar
Ji Z. Clinical observation on the efficacy and safety of the compound of metformin and glipizide in the treatment of type 2 diabetes with poor glycemic control. Master. Liaoning: China Medical University; 2011.
Google Scholar
Yao L, Lv XF, Ji X, Zhang JL. Clinical study on efficacy and safety of fixed-dose metformin/glipizide on type 2 diabetes mellitus. Chinese J Clin Pharmacol Ther. 2010;15:803–8.
Google Scholar
Yao J, Lu GZ, Yang JK, Liu JJ, Zhu LY, Lv XF, et al. Multi-center, randomized, double-masked, double-mimic active-controlled clinical trial of glipizide/metformin hydrochloride tablets for patients with type 2 diabetes. Chinese J Clin Pharmacol. 2008;24:387–91.
CAS
Google Scholar
Cui HM. Observation on the treatment of type 2 diabetes patients with secondary sulfonylurea failure. J Pract Med Tech. 2007;14:1280–1.
Google Scholar
Kan LBNE, Mai MTM, Dong JJ. Effect of metformin combined with repaglinide in the treatment of newly diagnosed type 2 diabetes. Med Hygiene. 2016;2:183.
Yang QY. Effect of metformin combined with repaglinide in the treatment of type 2 diabetes. Contemp Med Symp. 2016;14:19–20.
Google Scholar
Lei JJ, Chen YJ. Clinical observation of repaglinide in the treatment of elderly patients with type 2 diabetes. Chinese Commun Doctors. 2016;32:38–40.
Yang J. Efficacy of repaglinide combined with metformin in the treatment of young and middle-aged patients with type 2 diabetes. Diab New World. 2016;19:29–30.
Wang K. Preliminary observation on the effect of repaglinide combined with metformin in type 2 diabetes. Psychol Doctor. 2016;22:53–4.
Google Scholar
Li J. Efficacy of metformin combined with NovoNorm in the treatment of type 2 diabetes. Psychol Doctor. 2016;22:52–3.
Article
Google Scholar
Hu ZY. Effect of repaglinide combined with metformin in the treatment of newly diagnosed type 2 diabetes. Med Inf. 2016;29:64–5.
Google Scholar
Sun ZC. Efficacy of repaglinide combined with metformin in the treatment of type 2 diabetes. Diab New World. 2015;35:29–30.
Yu YY. Effect of repaglinide combined with metformin in the treatment of obese patients with type 2 diabetes. J North Pharm. 2015;12:23–4.
Google Scholar
Liang F. Clinical study of repaglinide combined with metformin in the treatment of patients with type 2 diabetes. Med Inf. 2015;28:96.
Google Scholar
Sun X. Application value of metformin combined with repaglinide in the treatment of newly diagnosed type 2 diabetes. Guide China Med. 2015;13:80–1.
Google Scholar
Li B. Effect of repaglinide combined with metformin in the treatment of type 2 diabetes. China Health Care Nutr. 2015;25:271.
Tan LL. Clinical efficacy of metformin combined with NovoNorm in the treatment of type 2 diabetes. Diab New World. 2014;34:11–2.
Jiang GJ. Efficacy of metformin combined with repaglinide in the treatment of type 2 diabetes. J Front Med. 2014;4:183–4.
Han XF. Efficacy of repaglinide combined with metformin in the treatment of type 2 diabetes. J China Prescription Drug. 2014;12:67–8.
Google Scholar
Huang JQ. Clinical observation of repaglinide and metformin in treatment of type 2 diabetes mellitus. Chinese Community Doctors. 2014;30:52+54.
Google Scholar
He M. Clinical observation of repaglinide combined with metformin in the treatment of type 2 diabetes. China Pract Med. 2013;8:144–5.
Google Scholar
He M. Clinical observation of repaglinide in the treatment of 61 cases of newly diagnosed type 2 diabetes. Chinese J Modern Drug Appl. 2013;7:149–50.
CAS
Google Scholar
Li L, Han CD. The clinical efficacy of repaglinide and metformin in the treatment of newly diagnosed type 2 diabetes. Chinese J Med Guide. 2013;15:2071+2073.
Google Scholar
Xu SL. Efficacy of repaglinide combined with metformin in the treatment of newly diagnosed type 2 diabetes. China Pract Med. 2013;8:144–6.
Google Scholar
Jin Y, Fan R, Cai JG. Clinical efficacy of metformin combined with NovoNorm in the treatment of type 2 diabetes. Guide China Med. 2012;10:185+188.
Google Scholar
Xue F. Efficacy of repaglinide combined with metformin in the treatment of new-onset type 2 diabetes. J Front Med. 2012;2:156–7.
Zhou YX. Efficacy of NovoNorm combined with metformin in the treatment of type 2 diabetes. J Front Med. 2012;2:152.
Google Scholar
Chen EF. Effect of NovoNorm combined with metformin on glucose control of type 2 diabetes. Strait Pharma J. 2012;24:231–3.
Google Scholar
Zhu AQ. Clinical experience of repaglinide combined with metformin in the treatment of type 2 diabetes. Chinese Commun Doctors. 2012;14:63.
CAS
Google Scholar
Jin SL. Efficacy observation of repaglinide and metformin in the treatment of newly diagnosed obese type 2 diabetes mellitus. China Pharmacy. 2011;22:1876–7.
CAS
Google Scholar
Chen YP, He YX. The efficacy of repaglinide in combination with metformin in newly diagnosed type 2 diabetes. National Med Front China. 2010;5:25–26+61.
Google Scholar
Yan GQ. Effect of repaglinide combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes. Contemp Med Forum. 2015;13:128–9.
Google Scholar
Yan XM. Efficacy of combined use of metformin and repaglinide in the treatment of 47 cases of type 2 diabetes. Contemp Med Forum. 2015;13:188–9.
Google Scholar
Shao JZ. Clinical efficacy of nateglinide in the treatment of type 2 diabetes. Contemp Med. 2013;19:142–4.
Google Scholar
Yao L, Wu YT, Zhang W, Xia CQ, Tian GX, Wang XB. Clinical effect of sitagliptin phosphate combined with metformin in treatment of type 2 diabetes mellitus. Chinese J Clin Healthcare. 2016;19:352–4.
CAS
Google Scholar
Pang XX. Efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes. J Pract Diabetol. 2016;12:42–3.
Article
Google Scholar
Han M. Efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes. World Latest Med Inf. 2016;16:79–80.
Google Scholar
Yu DY, Guan LX. Effect analysis of the incipient type 2 diabetes by metformin in combination with sitagliptin. China Health Standard Manage. 2016;7:104–5.
Google Scholar
Wang XL. Efficacy analysis of sitagliptin in the treatment of diabetes. Clin Res Pract. 2016;1:41.
Google Scholar
Qiao YC. Clinical study of sitagliptin phosphate combined with metformin in the treatment of newly diagnosed type 2 diabetes. Clin Res. 2016;24:71–2.
Google Scholar
Yang QM. Efficacy and safety of sitagliptin combined with metformin in the treatment of newly diagnosed type 2 diabetes. J Front Med. 2016;6:207–8.
Google Scholar
Wu XH. Effect of sitagliptin combined with metformin in the treatment of type 2 diabetes. Chinese J Crit Care Med. 2016;36:99–100.
Google Scholar
Xu YL. Efficacy and safety of sitagliptin combined with metformin in the treatment of type 2 diabetes. J Clin Med Lit. 2016;3:970–1.
Google Scholar
Xia CW. Application value of metformin combined with sitagliptin in patients with type 2 diabetes. Med Hygiene. 2016;2:221.
Li LQ. Clinical effect of metformin combined with sitagliptin phosphate in the treatment of newly diagnosed type 2 diabetes. World Clin Med. 2016;10:104+108.
Google Scholar
Hu GH. Clinical effect of metformin combined with sitagliptin in the treatment of newly diagnosed type 2 diabetes. Clin Res. 2016;24:234–5.
Google Scholar
Yan YH. Clinical observation of sitagliptin combined with metformin in the treatment of type 2 diabetes. J Med Theory Pract. 2016;29:3074–5.
Google Scholar
Li G. Clinical efficacy and safety of sitagliptin combined with metformin in the treatment of obese patients with type 2 diabetes. World Latest Med Inf. 2016;16:210–1.
Google Scholar
Xiong M. Clinical efficacy of metformin combined with sitagliptin in the treatment of patients with newly diagnosed diabetes. Chinese Baby. 2016;(3):16–7.
Zhang TT. Efficacy of metformin combined with sitagliptin in the treatment of patients with type 2 diabetes and its effect on blood lipid level. Modern Pract Med. 2016;28:1037–8.
Google Scholar
Qi BB, Song WC, Jiang DM, Ji M. Efficacy of dipeptidyl peptidase-4 inhibitor sitagliptin combined with metformin in the treatment of type 2 diabetes. Jiangsu Med J. 2016;42:1728–9.
Google Scholar
Yang F. Clinical efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes. J Today Health. 2016;15:26.
Google Scholar
Liu XL, Hu CH, Liu JH. Efficacy of sitagliptin combined with metformin in the treatment of newly diagnosed type 2 diabetes with non-alcoholic fatty liver disease. Modern Pract Med. 2016;28:894–5.
Google Scholar
Jiang X. Clinical effect of sitagliptin combined with metformin in the treatment of type 2 diabetes. Contin Med Educ. 2016;30:156–7.
Google Scholar
Fu HY. Efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes. China Rural Health. 2015;(2):47–8.
Huang YL. Effect of the new hypoglycemic drug sitagliptin in type 2 diabetes. Chinese Manipulation Rehabil Med. 2015;6:70–1.
Google Scholar
Yuan XJ, Ma LF, Yang H. Efficacy evaluation of metformin combined with sitagliptin phosphate in the treatment of newly diagnosed type 2 diabetes. Chinese J Modern Drug Appl. 2015;9:123–4.
CAS
Google Scholar
Li Z, He XT, Li T, Sun ZH. Clinical analysis of sitagliptin combined with metformin in treatment of type 2 diabetes. China Health Standard Manage. 2015;6:86–7.
Google Scholar
Wu QP. Clinical efficacy of sitagliptin in adjuvant treatment of obese patients with type 2 diabetes and its influence on their quality of life. Henan Med Res. 2015;24:11–3.
CAS
Google Scholar
Zhuo FT, Zhang LT, Gao XH. Effect of sitagliptin on pancreatic B cell function in the treatment of newly diagnosed type 2 diabetes. Pract Pharm Clin Remedies. 2015;18:622–4.
CAS
Google Scholar
Zhang J. Efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes. Chinese Pract J Rural Doctor. 2015;22:28–9.
Google Scholar
Chen P. Clinical observation of dipeptidyl peptidase IV inhibitor combined with metformin on treatment of patients with type 2 diabetes. J North Pharm. 2015;12:88–9.
CAS
Google Scholar
Fan SH. Effect of sitagliptin combined with metformin in the treatment of newly diagnosed type 2 diabetes. Modern Pract Med. 2015;27:1632–4.
Google Scholar
Zhang N, Wang Y, Liu YL. Effect of sitagliptin combined with metformin in the treatment of type 2 diabetes. Int Med Health Guid News. 2015;21:3211–3.
Google Scholar
Zhang HT, Wang F, Dong L. Efficacy of sitagliptin combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes. J Pract Diabetol. 2015;11:22–3.
Article
Google Scholar
Wang KL, Sun ZP, Han Y, Li HM. Therapeutic effect of DPP-4 inhibitor in the treatment of newly diagnosed type II diabetes. J Harbin Univ Commerce. 2014;30:659–61.
CAS
Google Scholar
Yang H, Fang CH. Effect of sitagliptin on serum hs-CRP of patients with newly diagnosed type 2 diabetes. Clin J Tradit Chinese Med. 2014;26:559–60.
Google Scholar
Liu SY, Lu XH. Efficacy of sitagliptin combined with metformin in the treatment of newly diagnosed type 2 diabetes. J China Prescription Drug. 2014;12:40–1.
Google Scholar
Guo YF, Zhang DQ. Clinical observation of sitagliptin phosphate tablets combined with metformin on treatment of elderly patients with type 2 diabetes. China Modern Med. 2014;21:93–4.
CAS
Google Scholar
Huang BX. Clinical observation of sitagliptin combined with metformin in the treatment of newly diagnosed diabetes. Chinese Commun Doctors. 2014;30:46–7.
Google Scholar
Qiu W. Metformin combined with sitagliptin in treating type 2 diabetes patients complicated by metabolic syndrome. Chinese J Modern Drug Appl. 2014;8:128–9.
Google Scholar
Shi AJ. Efficacy of sitagliptin combined with metformin in the treatment of obese patients with type 2 diabetes. Modern Diagn Treat. 2014;25:2743–5.
CAS
Google Scholar
Ye X. Effect of sitagliptin on islet β-cell function in type 2 diabetes. Modern Diagn Treat. 2014;25:5728–9.
CAS
Google Scholar
Wei ZX, Wu J, Hu HB, Ma WJ. Clinical efficacy of metformin combined with sitagliptin in the treatment of early type 2 diabetes. For all Health. 2014;8:496.
Google Scholar
Zhang LL. Clinical efficacy of sitagliptin and metformin in treatment of type 2 diabetes mellitus. China Med Pharm. 2013;3:65–6.
Google Scholar
Li WM. Study on the effectiveness and safety of sitagliptin and metformin in patients with type 2 diabetes. J Clin Exp Med. 2013;12:922–3.
Google Scholar
Pan YP, Zheng QD, Chen W. Effect of sitagliptin combined with metformin in the treatment of type 2 diabetes. Chinese J Rural Med Pharm. 2013;20:21–2.
Google Scholar
Jiao XM, Xu XP, Zhao J, Lv XF. Clinical observation on treatment of newly diagnosed type 2 diabetes with sitagliptin and metformin. Clin Focus. 2013;28:44–45+48.
CAS
Google Scholar
Zhang HY, Dong L. Clinical efficacy of sitagliptin combined with metformin in the treatment of new-onset type 2 diabetes. China Health Care Nutr. 2013;23:3900–1.
Google Scholar
Nie FR, Xu WL, Yang QF. The effect observation of metformin combined with sitagliptin in treatment of early type 2 diabetes mellitus. Pract J Cardiac Cereb Pneumal Vascular Dis. 2013;21:81–2.
Google Scholar
Zhao XH. Efficacy of sitagliptin combined with metformin in the treatment of type 2 diabetes. China Foreign Med Treat. 2012;31:77+79.
Google Scholar
Huang BX. Clinical observation of sitagliptin combined with metformin in the treatment of newly diagnosed diabetes. National Medi Front China. 2011;6:58.
Google Scholar
Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diab. 2012;4:227–37.
Article
CAS
Google Scholar
Su DY, Xue L, Pang WY. Efficacy of metformin combined with sitagliptin in the treatment of type 2 diabetes. China's Naturopathy. 2016;24:80–1.
Google Scholar
Yang YP, Ma LN. Efficacy of saxagliptin in patients with type 2 diabetes and its effects on hemorheology and vascular elasticity. Women's Health Res. 2016;(21):21–2.
Zhao JY, Chen B, Peng XD. Effect of saxagliptin therapy on pancreatic β-cell function and micro-inflammatory state of elderly patients with type 2 diabetes. J Hainan Med Univ. 2016;22:1254–7.
CAS
Google Scholar
Ding R, Ding GC, Cai RH. Efficacy and safety of dipeptidyl peptidase-4 inhibitor combined with metformin in the treatment of type 2 diabetes. Chinese J Biochem Pharm. 2016;36:154–156+159.
Google Scholar
Li M, Zhao W. Clinical efficacy of DPP-4 inhibitor combined with metformin in the treatment of type 2 diabetes. Guangzhou Med J. 2015;46:65–7.
Google Scholar
Wang SY, Li J, Cao GL, Zhou T. Effect of metformin alone or combined with saxagliptin on islet B cell functions in elderly patients with newly diagnosed type 2 diabetes. Pract Geriatr. 2015;29:232–4.
Google Scholar
Gao F. Clinical efficacy of saxagliptin in newly diagnosed type 2 diabetic patients. Int Med Health Guid News. 2015;21:2441–2.
Google Scholar
Li J. Experience in the application of saxagliptin combined with metformin in the treatment of type 2 diabetes. Modern Diagn Treat. 2015;26:516–7.
CAS
Google Scholar
Liang M. A randomized controlled study of saxagliptin combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes. Cap Food Med. 2015;22:75–6.
Feng J, Shi P. Efficacy evaluation of saxagliptin combined with metformin for treating 48 cases of elderly type 2 diabetes. China Pharmaceuticals. 2015;24:90–2.
CAS
Google Scholar
Sun L. The effect of saxagliptin in treatment of type 2 diabetes. China Modern Doctor. 2015;53:27–9.
CAS
Google Scholar
Geng XH. Efficacy of saxagliptin combined with metformin in the treatment of newly diagnosed type 2 diabetes. Chinese J Pract Med. 2015;42:72–3.
Google Scholar
Zhao SY. Effect of saxagliptin combined with metformin in the treatment of elderly patients with type 2 diabetes. Chinese J New Clin Med. 2015;8:642–4.
Google Scholar
Li XY, Liu MJ. Clinical efficacy and safety of saxagliptin combined with metformin on patients with type 2 diabetes. Chinese J Clin Pharmacol. 2015;31:169–171+192.
CAS
Google Scholar
Xie WS, Ou B. Efficacy of saxagliptin combined with metformin in the treatment of type 2 diabetes. Modern Diagn Treat. 2015;26:1784–5.
CAS
Google Scholar
Diao YL, Yu JH, Wang J. Clinical observation of saxagliptin combined with metformin in the treatment of type 2 diabetes. China Pharm. 2015;26:3761–3.
CAS
Google Scholar
Wan J, Li JL, Luo QR, Ceng JE. Efficacy of metformin or saxagliptin alone and in combination for treating type 2 diabetes. J Yangtze Univ. 2015;12:1–2+37.
Google Scholar
Sun Y, Li Y, Wang MZ. Efficacy of saxagliptin combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes. Chinese J Gerontol. 2014;34:4172–3.
CAS
Google Scholar
Lu JE, Pang LR, Gong WK. Efficacy of saxagliptin combined with metformin in the treatment of type 2 diabetes. Modern Pract Med. 2014;26:191–2.
Google Scholar
Dong L. Clinical efficacy and safety of saxagliptin combined with metformin in the treatment of type 2 diabetes. Guide China Med. 2014;12:117–8.
Google Scholar
Sun Y, Jin J, Wang MZ. A preliminary study on the efficacy of saxagliptin combined with metformin in the treatment of new-onset type 2 diabetes. Chinese J Control Endemic Dis. 2014;29:232–3.
Google Scholar
Fang Y, Zhang Y, Lin X. Clinical observation of saxagliptin and metformin in the treatment of type 2 diabetes. Modern Diagn Treat. 2013;24:3196–7.
CAS
Google Scholar
Li JJ, Liu CM, Dong XY, Zhang L. Saxagliptin add-on to metformin improves β cell functions in newly diagnosed patients with type 2 diabetes. China Med Pharm. 2013;3:16–8.
CAS
Google Scholar
Wen Q. Efficacy and safety of saxagliptin combined with metformin in the treatment of type 2 diabetes. Chinese-foreign Women's Health. 2013;21:156–7.
Li R, Wang HC, Liu MJ. Effect of vildagliptin combined with metformin on improving islet β-cell function and insulin resistance of patients with newly diagnosed type 2 diabetes. Modern J Integr Tradit Chinese Western Med. 2016;25:2575–7.
Google Scholar
Zhao XW, Tian J, Shen JX, Yang LX, Zhou YH. The effect of vildagliptin on pulmonary function in obese patients with type 2 diabetes treated with metformin. Anhui Med Pharm J. 2016;20:369–73.
Google Scholar
Xin CH, Liu F, Kuang JS. Clinical study of vildagliptin combined with metformin in the treatment of type 2 diabetes. Chinese J Modern Drug Appl. 2016;10:137–8.
Google Scholar
Meng ZL, Chu XQ. Efficacy of vildagliptin combined with metformin in the treatment of type 2 diabetes. J Clin Med Lit. 2016;3:49+52.
Google Scholar
Zheng ZP, Tian F, Zheng ZG, Yu M. Effects of vildagliptin combined with metformin on carotid intima-media thickness and serum adiponectin and homocysteine levels in type 2 diabetes mellitus patients with cardio-cerebral vascular disease. J Nanchang Univ. 2015;55:62–65+69.
CAS
Google Scholar
Shangguan HY, Xin B, Li J, Guo W, Luo Q. Clinical observation of vildagliptin combined with metformin in the treatment of type 2 diabetes. Chinese J Clin Res. 2015;28:1605–7.
CAS
Google Scholar
Xin CH, Li Z, Luo WG, Wang N, Kuang JS, Xue XF. Intervention effect of vildagliptin combined with metformin on risk factors of cardiovascular disease in overweight patients with type 2 diabetes mellitus. Med Pharm J Chinese People's Liberation Army. 2015;27:83–7.
CAS
Google Scholar
Xie LK, Qi CR, Sun YD. Clinical observation of vildagliptin combined with metformin in the treatment of 160 cases of type 2 diabetes with obesity. China Foreign Med Treat. 2015;34:108–9.
Liang CY, Tan SY, Wang YL. Clinical efficacy of vildagliptin (DPP-4 inhibitor) combined with oral hypoglycemic drugs in the treatment of 84 cases of type 2 diabetes. J Pract Diabetol. 2015;11:49–50.
Google Scholar
Gao XH. Clinical efficacy of metformin combined with vildagliptin in the treatment of type 2 diabetes. Chinese J Modern Drug Appl. 2015;9:105–6.
CAS
Google Scholar
Yan GJ. Clinical study of DPP-4 inhibitor combined with metformin in the treatment of type 2 diabetes. Modern Health. 2015;(6):38.
Jia XW, Jia HT. Short-term effects and safety analysis of metformin combined with vildagliptin in treatment of type 2 diabetes mellitus. China J Emerg Resuscitation Disaster Med. 2015;10:460–3.
Google Scholar
Li Y, He YQ, Wang GT. Efficacy of vildagliptin combined with metformin in the treatment of type 2 diabetes. China Rural Health. 2014;504.
Hao YH, Hao YJ. Effectiveness study of vildagliptin combined with metformin in the treatment of newly diagnosed type 2 diabetes. Shanxi Med J. 2014;43:1192–3.
Google Scholar
Peng L, Ma JH, You W, Xi Q. The influence of vildagliptin tablets on amylase levels of urine and serum in patients with type 2 diabetes. Hebei Med. 2014;20:723–6.
CAS
Google Scholar
Lu SM. Efficacy of DPP-4 inhibitor combined with metformin in the treatment of type 2 diabetes and its influence on cardiovascular risk factors. Clinical Educ Gen Pract. 2014;12:537–9.
Google Scholar
Zou Y, Huang SY, Yan YM, Wu M. Efficacy and safety of vildagliptin combined with metformin in the treatment of type 2 diabetes. J Pract Diabetol. 2014;10:37–8.
Google Scholar
Yan ZD, Hu JP, Tao DQ, Zhou HY. The efficacy and safety of vildagliptin combined with metformin in the treatment of type 2 diabetes. Chinese J Difficult Complicated Cases. 2014;13:156–8.
CAS
Google Scholar
Lai KB, Shi ZZ, Huang ZC, Guo ZQ, Liao QH, Chen YH. Effects of vildagliptin combined with metformin on IL-6, TNF-a, CRP in patients with type 2 diabetes. Modern Diagn Treat. 2014;25:5544–5.
Cheng LY. DPP-4 inhibitor combined with metformin in the treatment of 75 cases of type 2 diabetes. J Yangtze Univ. 2014;11:66–8.
CAS
Google Scholar
Chen XS, Li GY, Wu JY. Clinical efficacy of vildagliptin combined with metformin in the treatment of elderly patients with type 2 diabetes. Cap Med. 2014;21:73–4.
Liu XH, Zeng CH, Rao YL. Clinical application value of metformin combined with vildagliptin in the treatment of type 2 diabetes. Chinese J Difficult Complicated Cases. 2013;12:137–8.
CAS
Google Scholar
Yan J. Clinical observation on the combined effect of vildagliptin and metformin in patients with type 2 diabetes mellitus. Master. Jilin: Jilin University; 2013.
Google Scholar
Zhao TQ, Wang LM. Therapeutic comparison between pure metformin and DPP-4 inhibitor as add-on therapy to metformin in T2DM treatment. Chinese J Diab. 2012;20:367–9.
CAS
Google Scholar
Ji LN, Pan CY, Lu JM, Li H, Zhu DL, Li Q, et al. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION). Diab Obes Metab. 2016;18:775–82.
Article
CAS
Google Scholar
Su Y, Su YL, Lv LF, Wang LM, Li QZ, Zhao ZG. A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Exp Ther Med. 2014;7:799–803.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diab Obes Metab. 2012;14:737–44.
Article
CAS
Google Scholar
Zhao XW, Tian J, Shen JX, Yang LX, Zhou YH. Clinical observation of the effect of linagliptin on cardiovascular risk factors in obese type 2 diabetic patients treated with metformin. Guizhou Med J. 2016;40:40–2.
CAS
Google Scholar
Zheng FP. The effects of dipeptidyl peptidase-4 inhibitor alogliptin on lipid profile in patients with newly diagnosed type 2 diabetes mellitus. Master. Liaoning: China Medical University; 2016.
Google Scholar
Weng Y, Wang JK, Song YL, Tang YS, Li Y, Zheng FP, Li CL, Zhou YJ. Efficacy and safety of alogliptin combined with metformin in the treatment of type 2 diabetes mellitus and nonalcoholic fatty liver disease. Pract Pharm Clin Remedies. 2016;19:713–5.
CAS
Google Scholar
Zhao YP, Liu J, Tai H, Dong QY, Kuang JS. Effect of alogliptin combined with metformin on hemodynamic changes of retrobulbar arterytype and oxidative stress indexes in type 2 diabetes patients. Modern J Integr Tradit Chinese Western Med. 2016;25:1163–1165+1182.
Google Scholar
Dong QY, Lin L, Kuang JS. Effect of alogliptin on lung function in obese patients with type 2 diabetes treated with metformin. J Clin Pulm Med. 2016;21:392–6.
Google Scholar
Dong QY, Kuang JS. The effect of alogliptin on content of oxidative related substances in obese type 2 diabetes patients treated by metformin. Lab Med Clin. 2016;13:328–31.
CAS
Google Scholar
Wang L. Efficacy and safety of alogliptin combined with metformin in the treatment of patients with newly diagnosed type 2 diabetes. Med Forum. 2016;20:545–6.
Google Scholar
Tai H, Wang MY, Zhao YP, Li LB, Dong QY, Liu XG, Kuang JS. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy. Medicine. 2016;95:1–11.
Article
Google Scholar
Su Y, Lv LF, Li QZ, Zhao ZG, Su YL. The clinical research on the treatment of type 2 diabetes mellitus by DPP-4 inhibitor. Chinese J Diab. 2014;22:886–9.
CAS
Google Scholar
Li CY. Efficacy of rosiglitazone combined with metformin capsule in the treatment of type 2 diabetes. J Pract Med Tech. 2016;23:94–5.
Google Scholar
Xie LH. Clinical observation of metformin combined with pioglitazone in the treatment of incipient type 2 diabetes. China Pharm. 2016;27:1629–31.
Google Scholar
Li JY. Prognostic observation of rosiglitazone combined with metformin in the treatment of type 2 diabetes. Diab New World. 2014;34:11+13.
Lei CY, Liang J. Clinical observation of metformin combination therapy for treating type 2 diabetes. Med Inf. 2014;27:80.
Yang XD, Li WQ. Rosiglitazone hydrochloride combined with metformin in the treatment of 75 cases of type 2 diabetes. J Commun Med. 2013;11:51–2.
Google Scholar
Wang SQ, Wang JY, Chen YQ, Man J. Effects of rosiglitazone on serum adiponectin and visfatin levels in patients with type 2 diabetes mellitus. Int Med Health Guid News. 2013;19:1904–7.
Google Scholar
Yu CY. Clinical study of metformin combined with rosiglitazone in the treatment of type 2 diabetes. Chinese Foreign Med Res. 2013;11:21–2.
Article
CAS
Google Scholar
Gao Y. Clinical study of metformin combined with rosiglitazone in the treatment of type 2 diabetes. Chinese J Pract Med. 2013;40:68–9.
Google Scholar
Liu M. Efficacy of rosiglitazone tartrate combined with metformin in the treatment of type 2 diabetes. Guide China Med. 2012;10:578–9.
Google Scholar
Luo YJ. Clinical curative effect analysis of rosiglitazone combined with metformin in treatment of type 2 diabetes. China Modern Med. 2012;19:82–3.
CAS
Google Scholar
Wang SY, Shen TT. Observation of curative effect of rosiglitazone combined with metformin on type 2 diabetes mellitus. Modern J Integr Tradit Chinese Western Med. 2012;21:1046–1047+1050.
CAS
Google Scholar
Si JL. Evaluation on the efficacy and safety of metformin combined with rosiglitazone in treatment of type II diabetes. Med J West China. 2012;24:2326–2327+2330.
Google Scholar
Liu WJ, Luo Y, Guo L. The clinical observation of rosiglitazone combined with metformin in treatment of type 2 diabetes mellitus. Med J West China. 2011;23:2184–2185+2187.
Google Scholar
Li YG, Zeng JE, Ning SX. Clinical observation of rosiglitazone combined with metformin sustained-release tablets in the treatment of newly diagnosed type 2 diabetes. J Clin Exp Med. 2011;10:128–9.
Google Scholar
Xie YQ. Clinical observation of rosiglitazone combined with metformin in the treatment of new-onset type 2 diabetes. Chinese J Modern Drug Appl. 2010;4:53.
Google Scholar
Qi MP, Wei CY, Wu SM. Rosiglitazone combined with metformin rapidly improves insulin resistance. J Baotou Med Coll. 2010;26:64–5.
Google Scholar
Li GH. The evaluation of therapeutic effect and safety of rosiglitazone combined with metformin on incipient type 2 diabetes. Hebei Med J. 2010;32:1995–7.
Google Scholar
Zhong FD, Guo XZ, Sha YC, Jiao GW, Xi YN, Mo LL. Effect of rosiglitazone combined with metformin sustained-release tablets in the treatment of newly diagnosed type 2 diabetes. Med J Commun. 2009;23:48–9.
Google Scholar
Xia ZX, Guo YX, Zhou M, Yan J. Efficacy of metformin sustained-release tablets combined with rosiglitazone maleate in the treatment of type 2 diabetes. J Clin Exp Med. 2009;8:27–8.
CAS
Google Scholar
Li Y, Pang J, Li SL, Xu J, Bai XG. Relationship between insulin resistance and high-sensitivity C-reactive protein in obese patients with type 2 diabetes and the treatment effects of insulin sensitizer. J Pract Med. 2009;25:4158–60.
CAS
Google Scholar
Han SH, Hu HK, Zhang YF, Huang Z, Chen YX. Efficacy of rosiglitazone combined with metformin in the treatment of type 2 diabetes. Sichuan Med J. 2007;28:51–2.
Google Scholar
Wang SF, Qu XH, Zhao Y. Comparison of the efficacy of rosiglitazone and metformin in the treatment of new-onset type 2 diabetes. Chinese J Diabetes. 2006;14:415–6.
CAS
Google Scholar
Zhang GQ. Clinical efficacy of Avandia combined with Glucophage in the treatment of type 2 diabetes. J Nongken Med. 2004;26:275–6.
CAS
Google Scholar
Chen HM, Li HB, Qiu G, Dai SR, Tang YX. Effect of pioglitazone combined with metformin on serum retinol-binding protein 4 (RBP4) in patients with newly diagnosed type 2 diabetes. Chinese J Clin Healthcare. 2016;19:366–8.
CAS
Google Scholar
Zhang CR. To observe the intervention effect of pioglitazone on blood lipid of type 2 diabetes mellitus. Diab New World. 2016;19:39–51.
Li SQ. Clinical efficacy evaluation on hypoglycemic effect of metformin hydrochloride combined with pioglitazone hydrochloride in patients with type 2 diabetes. Anti-Infect Pharm. 2016;13:464–6.
Google Scholar
Jin HM. Effects of pioglitazone and metformin on blood lipids and vascular endothelial cell function in patients with type 2 diabetes. World Latest Med Inf. 2016;16:118+120.
Google Scholar
Zhu WH. Efficacy of metformin combined with pioglitazone in the treatment of type 2 diabetes. J North Pharm. 2015;12:64–5.
Google Scholar
Song RS, Liu FY, Liu FZ. A comparison study on glycemic control effect and safety of pioglitazone/metformin fixed dose combination and metformin monotherapy in the treatment of type 2 diabetes. Health Guide. 2015;20:81.
Google Scholar
Wen L, Zhang JW, Li BY, Chen N. Efficacy of pioglitazone combined with metformin in the treatment of obese type 2 diabetes. Med Inf. 2015;28:279.
Google Scholar
Liu SH. Effect of metformin combined with pioglitazone in the treatment of type 2 diabetes. Clin Res. 2015;23:59–60.
Google Scholar
Chang C. Clinical effect of pioglitazone combined with metformin in the treatment of newly diagnosed type 2 diabetes. Med Inf. 2015;28:194–5.
Google Scholar
Zhang CH. Clinical efficacy of metformin combined with pioglitazone in the treatment of type 2 diabetes. World Latest Med Inf. 2015;15:112–1.
Lu S. Efficacy of pioglitazone in the treatment of type 2 diabetes patients with obesity. Med Aesthetics Cosmetol. 2015;24:298.
Zhou YQ, Jin F, Zhang M, Hu JS. Effect of metformin combined with pioglitazone in the treatment of elderly patients with type 2 diabetes. J Front Med. 2015;5:60–1.
Google Scholar
Ren YL. Effect of pioglitazone and metformin in the treatment of type 2 diabetes. China Health Standard Manage. 2015;6:103–4.
Google Scholar
Wang T. Effect analysis of metformin combined with pioglitazone in the treatment of type 2 diabetes. Chinese J Clin Ration Drug Use. 2015;8:40–1.
Google Scholar
Zhu XX. Efficacy of metformin combined with pioglitazone in the treatment of type 2 diabetes. Diab New World. 2015;35:28+30.
Yang HM, Qin QH. The curative effect of pioglitazone joint metformin in treatment of type 2 diabetes patients. J Front Med. 2015;5:146–8.
Google Scholar
Yang XL. Clinical observation of pioglitazone hydrochloride combined with metformin sustained-release tablets in the treatment of 180 cases of type 2 diabetes. Contemp Med. 2015;21:138–9.
Google Scholar
Yang QM. Analysis of effectiveness of pioglitazone hydrochloride combined with metformin sustained-release tablets in the treatment of type 2 diabetes mellitus. Chinese Commun Doctors. 2015;31:23–4.
CAS
Google Scholar
Ma ZX. Efficacy of pioglitazone hydrochloride combined with metformin sustained-release tablets in the treatment of type 2 diabetes. Diab New World. 2015;35:52–3.
Liu HY. Efficacy of metformin combined with pioglitazone in treatment of type 2 diabetes. China Modern Doctor. 2014;52:49–50+53.
CAS
Google Scholar
Deng MX. Clinical observation on the effect of metformin combined with pioglitazone on newly diagnosed type 2 diabetes patients. China Health Care Nutr. 2014;24:1798–9.
Google Scholar
Shen CM. Clinical value analysis of metformin combined with pioglitazone in the treatment of refractory type 2 diabetes. Shaanxi Med J. 2014;43:1077–9.
CAS
Google Scholar
Li HJ, Zhang DH, Liu HJ. Effect of pioglitazone combined with metformin on insulin resistance and adipocytokine levels in patients with type 2 diabetes. Chinese J Gerontol. 2014;34:2416–8.
CAS
Google Scholar
Du YJ. Efficacy of metformin combined with pioglitazone in the treatment of type 2 diabetes. Health Res. 2014;34:212–3.
CAS
Google Scholar
Zhou JJ. Efficacy of pioglitazone combined with metformin in the treatment of type 2 diabetes. Med Inf. 2014;27:74.
Google Scholar
Wang H, Ye D. Effects of pioglitazone joint metformin on vascular endothelial cell function and insulin resistance in type 2 diabetes patients. China Modern Doctor. 2013;51:25–7.
Google Scholar
Zhong J. Efficacy of metformin hydrochloride combined with pioglitazone in the treatment of type 2 diabetes. Seek Med Ask Med. 2013;11:303–4.
Google Scholar
Li X. Clinical efficacy of pioglitazone combined with metformin in the treatment of 59 cases of type 2 diabetes. Chinese J Clin Ration Drug Use. 2013;6:42–3.
Google Scholar
Xiao XY. Efficacy of metformin combined with pioglitazone in the treatment of 48 cases of newly diagnosed type 2 diabetes. Med Innov China. 2013;10:37–8.
CAS
Google Scholar
Yan T, Yang R, Yu DF, Wang J, Sun J, Cheng YZ, Yang XY, He L, Cai DH. Effects of pioglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin, and interleukin-6 levels in patients with type 2 diabetes. Chinese J Endocrinol Metab. 2013;29:509–11.
CAS
Google Scholar
Bi XS. Therapeutic efficacy of metformin combined with pioglitazone in treatment of type 2 diabetes. Prev Treat Cardiovasc Dis. 2013;(1):49–51.
Zhu YF, Li B. Clinical analysis of metformin combined with pioglitazone in the treatment of 134 cases of type 2 diabetes. China Health Industry. 2012;9:57–8.
Google Scholar
Yang YB. Clinical observation of pioglitazone hydrochloride combined with metformin in the treatment of type 2 diabetes. Chinese Foreign Med Res. 2012;10:23–4.
Google Scholar
Yang F. Clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes. Modern Diagn Treat. 2012;23:1360–2.
CAS
Google Scholar
Jiang H. Efficacy of metformin combined with pioglitazone in the treatment of type 2 diabetes. China Pract Med. 2012;7:153–5.
Google Scholar
Shao P, Shen M. Efficacy of metformin combined with pioglitazone in the treatment of new-onset type 2 diabetes. Chinese Foreign Med Res. 2012;10:22.
Google Scholar
Yuan ML. Clinical observation of the combination of metformin and pioglitazone in treating obese patients with newly diagnosed type 2 diabetes mellitus. Chinese J Med Guide. 2012;14:433–4.
Google Scholar
Teng YP. A controlled study of pioglitazone combined with metformin in treating type 2 diabetes. China Health Ind. 2012;9:5–6.
Google Scholar
Du SZ. Clinical efficacy of pioglitazone combined with metformin for the treatment of type 2 diabetes mellitus. J Clin Res. 2011;28:1941–3.
CAS
Google Scholar
Yang Y, Qi Y, Xie J, Ye YQ, Liu ZP, Xing XL, Yao CH, Bai RJ, Qiu YZ. Effect of pioglitazone on blood lipid level of patients with newly diagnosed type 2 diabetes and its clinical significance. Chinese J Microcirc. 2011;21:30–31+34.
CAS
Google Scholar
Guo HF. Efficacy of pioglitazone and metformin in the treatment of type 2 diabetes. Chinese J Misdiagnostics. 2011;11:3136–7.
Google Scholar
Wang GH. Pioglitazone and metformin in the treatment of new-onset type 2 diabetes. J Jianghan Univ. 2010;38:84–5.
CAS
Google Scholar
Hong YJ, Guo WY. Analysis on clinical efficacy and safety of pioglitazone combined with metformin in the treatment of type 2 diabetes. China Pharm. 2010;21:2258–9.
CAS
Google Scholar
Wang XP, Chen YS, Song PY, Wang JH, Wen AM. Efficacy of pioglitazone and metformin in the treatment of type 2 diabetes. Heilongjiang Med J. 2009;22:30–1.
Google Scholar
Deng JH. Efficacy of pioglitazone combined with metformin in the treatment of type 2 diabetes. Proc Clin Med. 2009;18:809–11.
Google Scholar
Cao XJ. Pioglitazone hydrochloride combined with metformin in the treatment of newly diagnosed type 2 diabetes. Modern J Integr Tradit Chinese Western Med. 2009;18:1360–1.
Google Scholar
Wang QK, Weng XY. Observation on the effect of pioglitazone hydrochloride combined with metformin in type 2 diabetes. China Trop Med. 2007;7:1118+1164.
Google Scholar
Wang LH. Efficacy of pioglitazone and metformin in the treatment of type 2 diabetes. Heilongjiang Med J. 2010;23:623.
Google Scholar
Zhang YM, Hu CH, Liu JH. Effect of pioglitazone combined with metformin on homocysteine in patients with type 2 diabetes and fatty liver. Prev Treat Cardio Cereb Vasc Dis. 2013;13:410–1.
Google Scholar
Liu SJ. Efficacy of insulin glargine combined with metformin in the treatment of type 2 diabetes. China Pract Med. 2015;10:157–8.
CAS
Google Scholar
Zhang WH, Hu HX. Efficacy and safety of insulin glargine combined with metformin in intensive treatment of new-onset type 2 diabetes. J North Pharm. 2015;12:144–5.
Google Scholar
Ma L. Efficacy of insulin glargine combined with metformin in the treatment of type 2 diabetes. Jilin Med J. 2015;36:714–5.
CAS
Google Scholar
He RY. Clinical efficacy and safety of insulin glargine injection combined with metformin in the treatment of type 2 diabetes. Diab New World. 2015;35:36.
Li M. Clinical study of insulin glargine combined with metformin in the treatment of type 2 diabetes. Med Hygiene. 2015;1:149.
He YF, Zhao Q. A randomized controlled study of metformin monotherapy and different combination regimens in the treatment of type 2 diabetes. Chinese Manipulation Rehabil Med. 2014;5:122–3.
Google Scholar
Lv CY. Clinical observation of the effect of insulin glargine combined with metformin on fasting blood glucose. J Pract Diabetol. 2008;4:28–9.
Google Scholar
Yao JY. Efficacy of insulin glargine combined with metformin in the treatment of type 2 diabetes. China Pharmaceuticals. 2013;22:4–5.
CAS
Google Scholar
Ma YM, Huang Y. Clinical observation of insulin glargine combined with metformin in treatment of type 2 diabetes. China J Pharm Econ. 2015;10:83–4.
Li RL. Effects of Novolin N combined with metformin on blood glucose, C-peptide and CRP in patients with type 2 diabetes. Modern J Integr Tradit Chinese Western Med. 2014;23:1207–9.
CAS
Google Scholar
Wang JQ. Clinical study of insulin aspart 30 combined with metformin in the treatment of type 2 diabetes. Chinese-foreign Women’s Health. 2014;22:173.
Wang DY. Clinical efficacy of insulin detemir combined with metformin in the treatment of type 2 diabetes. Strait Pharm J. 2011;23:124–5.
Google Scholar
Sun B. Clinical observation of insulin combined with metformin in the treatment of newly diagnosed type 2 diabetes. Chinese J Misdiagnostics. 2009;9:2839.
Google Scholar
Cao YQ, Fan HB, Lu QH, Dong Y, Gu YP. Effect observation on metformin combined with Humulin in treatment of obese type 2 diabetes with onset diabetic foot. Drugs Clin. 2014;29:615–8.
CAS
Google Scholar
Wang GF, Bai YX, Lou DL, Liu HX, Wang B, Guo Y, Liu Y. Effect of intensive insulin therapy on β-cell function in overweight patients with newly diagnosed type 2 diabetes. Guide China Med. 2013;11:186–7.
Google Scholar
Wu ZY. Effect of insulin aspart 30 combined with metformin in the treatment of elderly patients with newly diagnosed type 2 diabetes. Chinese Med J Metallurgical Ind. 2016;33:392.
Google Scholar
Jiang LY. Clinical observation of exenatide combined with metformin in the treatment of obese type 2 diabetes. Chinese J Trauma Disabil Med. 2015;23:53–5.
Google Scholar
Hu H. Efficacy of exenatide combined with metformin in the treatment of type 2 diabetes. Diab New World. 2015;35:26–7.
Li BW, Yu JL, Zhang H, Jiang L, Li YL, Li N, Zhang P. Effect of GLP-1 receptor agonist on early insulin secretion and body weight in type 2 diabetes. Med Inf. 2015;28:142–3.
Google Scholar
Pan NN. Clinical observation of exenatide combined with metformin in the treatment of elderly type 2 diabetes. Chinese J Clin Ration Drug Use. 2014;7:76–7.
Google Scholar
Niu L, Hong T, Zhao S. Clinical efficacy of exenatide combined with metformin in treatment of obese type 2 diabetes. Chinese J Hosp Pharm. 2013;33:1418–20.
CAS
Google Scholar
Wang F, Ren HQ, Shen XB. Effect of liraglutide combined with metformin on clinical outcomes and HOMA-β, HOMA-IR index in obese patients with type 2 diabetes. Guizhou Med J. 2016;40:1159–61.
CAS
Google Scholar
Wang XC. The role of liraglutide on the body fat composition of obese patients with type 2 diabetes among the Uygur nationality in Xinjiang. Master. Xinjiang: Xinjiang Medical University; 2016.
Google Scholar
Song WR. Observation of clinical effect of liraglutide combined with metformin in the treatment of obese patients with type 2 diabetes. Drug Eval. 2016;13:23–6.
CAS
Google Scholar
Wang CX, Gao H, Wang YL. Effect of liraglutide combined with metformin on vascular endothelial function in the Uygur and the Han nationality obese patients with type 2 diabetes in Xinjiang. J Xinjiang Med Univ. 2016;39:968–971+974.
CAS
Google Scholar
Fang ZD. Follow up study of liraglutide long-term hypoglycemic treatment on delaying disease progression in patients with type 2 diabetes. Syst Med. 2016;1:49–51.
Google Scholar
Zhao YL, Chen JB, Zhang FJ, Chu YN, Zhang XK. Effect of liraglutide combined with metformin on glycolipid metabolism in early diabetic patients. Chinese J Pract Med. 2016;43:104–5.
Google Scholar
Wei DH. Clinical analysis of metformin combined with liraglutide in the treatment of type 2 diabetes. Med Hygiene. 2016;2:217.
Gao HM, Shang Y. Clinical curative effect of liraglutide combined with metformin in treatment of type 2 diabetes. China Foreign Med Treat. 2016;35:137–9.
Sun F. Clinical effect of liraglutide combined with metformin in the treatment of type 2 diabetes. Clin Res Pract. 2016;1:33–4.
Google Scholar
Xue GF, Yang XR. Clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes. J Today Health. 2016;15:160.
Google Scholar
Yao YN, Zhu ZL, Wang YL. Clinical efficacy of liraglutide combined with metformin hydrochloride in the treatment of Uygur and Han nationality obese patients with type 2 diabetes. J Xinjiang Med Univ. 2015;38:1527–1530+1535.
CAS
Google Scholar
Liu CL. Influence of liraglutide on main physiological indices of type 2 diabetes patients. China Pharmaceuticals. 2015;24:30–1.
Google Scholar
Zhao FL, Qi M, Liu H. Effect of liraglutide combined with metformin on type 2 diabetes patients with obesity and its impact on micro-inflammatory state. China J Modern Med. 2015;25:43–6.
CAS
Google Scholar
Wang HQ, Tang GW, Lin SY. Effects of Victoza combined with metformin on insulin resistance in patient with type 2 diabetes. Jilin Med J. 2015;36:3859–61.
CAS
Google Scholar
Yu YZ. Clinical effect of liraglutide (Victoza) in the treatment of diabetes. World Latest Med Inf. 2015;15:117.
Google Scholar
He J, Jiang Q. Clinical effects of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus. China Modern Med. 2014;21:80–2.
Google Scholar
Tian SJ, Li D. Effect of metformin combined with liraglutide in the treatment of newly diagnosed type 2 diabetes. Clin Med China. 2013;29:939–41.
Google Scholar
Liang C, Zhou L. Clinical efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus. Chinese J Biochem Pharm. 2012;33:656–8.
CAS
Google Scholar
Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L, Group P. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;366:l4697.
Article
PubMed
PubMed Central
Google Scholar
McKenzie JE, Herbison GP, Deeks JJ. Impact of analysing continuous outcomes using final values, change scores and analysis of covariance on the performance of meta-analytic methods: a simulation study. Res Synth Methods. 2016;7:371–86.
Article
PubMed
Google Scholar
Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019;365:l1328.
Article
PubMed
PubMed Central
Google Scholar
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–91.
Article
PubMed
CAS
Google Scholar
Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472.
Article
PubMed
PubMed Central
Google Scholar
Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14:417–28.
Article
PubMed
Google Scholar
Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison [computer program]. Version 1.0. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
Google Scholar
Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect evidence: indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
Google Scholar
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. https://www.nice.org.uk/process/pmg9/chapter/the-reference-case. Accessed 1 Aug 2019.
Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30:1267–73.
Article
PubMed
CAS
Google Scholar
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care. 2012;35:1364–79.
Article
CAS
Google Scholar
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diab Care. 2019;42:S90–S102.
Article
Google Scholar
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.
Article
PubMed
CAS
Google Scholar
Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther. 2008;25:752–74.
Article
PubMed
CAS
Google Scholar
Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Adv Ther. 2010;27:814–27.
Article
PubMed
Google Scholar
Wu J, Zheng Y. Cost-utility analysis of biphasic insulin aspart 30 versus premixed human insulin in Chinese patients with type 2 diabetes. Chinese Pharm J. 2010;45:1116–20.
Google Scholar
Li H, Xu F, Wang F. Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chinese J New Drugs. 2011;20:2163–70.
Google Scholar
Chen X, Wei Y, Li W, Yang W, Guan H. Cost-effectiveness analysis of switch from premix human insulin to biphasic insulin aspart 30 in Chinese patients with type 2 diabetes mellitus. Chinese J Diab Mellitus. 2015;7:741–7.
Google Scholar
Gu S, Wang X, Qiao Q, Gao W, Wang J, Dong H. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diab Obes Metab. 2017;19:1688–97.
Article
Google Scholar
Gu S, Zeng Y, Yu D, Hu X, Dong H. Cost-effectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China. PLoS One. 2016;11:e0167190.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gu S, Mu Y, Zhai S, Zeng Y, Zhen X, Dong H. Cost-effectiveness of dapagliflozin versus acarbose as a monotherapy in type 2 diabetes in China. PLoS One. 2016;11:e0165629.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gu S, Deng J, Shi L, Mu Y, Dong H. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in type 2 diabetes in China. J Med Econ. 2015;18:808–20.
Article
PubMed
Google Scholar
Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017;33:359–69.
Article
PubMed
CAS
Google Scholar
Zhu J, Chen W. Economic evaluation of vildagliptin as add-on therapy to metformin in diabetes mellitus treatment in China. China J Pharm Econ. 2013;8:11–6.
Zhu J, Chen W. Pharmacoeconomic evaluation of sitagliptin in the treatment of type 2 diabetes mellitus. China Pharm. 2016;27:157–62.
Google Scholar
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
Article
PubMed
PubMed Central
CAS
Google Scholar